- Active, not recruiting
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
Updated: Sep 29, 2022
MCARH109 CART
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment. The study treatment could stop the growth of the cancer, but it could also cause side effects.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT04555551
Official Title: Phase I Trial of G Protein-coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
First Posted : September 18, 2020
Click here for details on ClinicalTrials.gov
autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109
GPRC5D-Targeted CAR T Cells for Myeloma
N Engl J Med; 2022 Sep 29
Conclusions: The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04555551.).
827 Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 704. Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapies
Hematology Disease Topics & Pathways:
Clinical Trials, Biological, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinically Relevant, Diseases, Therapies, Lymphoid Malignancies
Monday, December 13, 2021: 5:30 PM
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma
Blood Cancer Discov;2020 Sep
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Sci Transl Med;2019 Mar 27
- CART
- MCARH109
- New York: Memorial Sloan-Kettering Cancer Center New York
Location
United States, New York
RELATED GPRC5D POSTS
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma